GNI Group, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GNI Group, Ltd.
System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.
The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.
- Generic Drugs
- Other Names / Subsidiaries
- Shanghai Genomics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.